Consolidated Statements of Stockholders' Equity - USD ($)	Series AAA	Series B Preferred Stock	Series AAA Preferred Stock	Preferred Stock	Common Stock	Nonvoting Convertible Preferred Stock	Additional Paid-In Capital	Retained Earnings	Deficit Attributable to noncontrolling interest	Noncontrolling Interest	Contributed Capital	Accumulated Other Comprehensive Income (Loss)	Total
Beginning balance, Shares at Sep. 30, 2013	94,852	725,409	40,000	2,063,821	2,390,304,145	0
Beginning balance, Amount at Sep. 30, 2013	$ 9	$ 73	$ 4	$ 207	$ 239,029	$ 0	$ 14,845,671	$ 24,542,314		$ 5,765	$ 509,355	$ (41,329,361)	$ (1,186,934)
Common Shares issued for debt, Shares					120,000,000
Common Shares issued for debt, Amount					$ 12,000		32,500						44,500
Common Stock issued to Consultant, Shares					200,000
Common Stock issued to Consultant, Amount					$ 20		360						380
Common Shares issued for debt (B), Shares					120,000
Common Shares issued for debt (B), Amount					$ 12,000								12,000
Common Shares issued for debt (C), Shares					150,000,000
Common Shares issued for debt (C), Amount					$ 15,000								15,000
Common Shares issued to vendor, Shares					30,000,000
Common Shares issued to vendor, Amount							45,000						48,000
Common stock of subsidiary issued for Cash, Amount							100,000						100,000
Common stock of subsidiary issued for Cash (B), Amount							100,000						100,000
Common stock of subsidiary issued for Cash (C), Amount							100,000						100,000
Loss recognized on issuance of shares for less than fair value							648,500						648,500
Accumulated Other Comprehensive Income (Loss)												(4,000)	(4,000)
Noncontrolling interest recognized							(6,597)			6,597			0
Net Income (loss)								(920,888)					(920,888)
Ending balance, Shares at Dec. 31, 2013	94,852	725,409	40,000	2,063,821	2,810,504,145	0
Ending balance, Amount at Dec. 31, 2013	$ 9	$ 73	$ 4	$ 207	$ 281,049	$ 0	15,865,434	23,621,426	$ 0	12,362	509,355	(41,333,361)	(1,043,442)
Common Shares issued for debt, Shares					140,000,000
Common Shares issued for debt, Amount					$ 14,000		70						14,070
Common Shares issued for debt (B), Shares					500,000
Common Shares issued for debt (B), Amount					$ 50		950						1,000
Loss recognized on issuance of shares for less than fair value							336,230						336,230
Accumulated Other Comprehensive Income (Loss)												8,000	8,000
Noncontrolling interest recognized							(82,664)			82,664			0
Net Income (loss)								(529,555)					(529,555)
Ending balance, Shares at Mar. 31, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Ending balance, Amount at Mar. 31, 2014	$ 9	$ 73	$ 4	$ 207	$ 295,099	$ 0	16,120,020	23,091,871	0	95,026	509,355	(41,325,361)	1,213,696
Accumulated Other Comprehensive Income (Loss)												(6,000)	(6,000)
Noncontrolling interest recognized							47,466			(47,466)			0
Net Income (loss)								(246,447)					(246,447)
Ending balance, Shares at Jun. 30, 2014	94,852	725,409	40,000	2,063,821	2,951,004,145	0
Ending balance, Amount at Jun. 30, 2014	$ 9	$ 73	$ 4	$ 207	$ 295,099	$ 0	16,167,486	22,845,424	0	47,560	509,355	(41,331,361)	(1,466,144)
Common Shares issued for cash, Shares					45,000,000
Common Shares issued for cash, Amount					$ 45,000		95,500						100,000
Common Shares issued for debt, Shares					37,500,000
Common Shares issued for debt, Amount					$ 3,750		33,750						37,500
Common Stock issued to Consultant, Shares					8,896,797
Common Stock issued to Consultant, Amount					$ 890		24,910						25,800
Common Shares issued for debt (B), Shares					37,500,000
Common Shares issued for debt (B), Amount					$ 3,750		33,750						37,500
Loss recognized on issuance of shares for less than fair value							127,500						127,500
Accumulated Other Comprehensive Income (Loss)												(2,000)	(2,000)
Noncontrolling interest recognized							27,543			(27,543)			0
Net Income (loss)								(384,068)					(384,068)
Ending balance, Shares at Sep. 30, 2014	94,852	725,409	40,000	2,063,821	3,079,900,942	0
Ending balance, Amount at Sep. 30, 2014	$ 9	$ 73	$ 4	$ 207	$ 307,989	$ 0	16,510,439	22,461,356	0	20,017	509,355	(41,333,361)	(1,523,912)
Common Shares issued for debt, Shares					100,000,000
Common Shares issued for debt, Amount					$ 10,000		27,500						37,500
Common Shares issued for debt (B), Shares					100,000,000
Common Shares issued for debt (B), Amount					$ 10,000		25,000						35,000
Common Shares issued for debt (C), Shares					200,000
Common Shares issued for debt (C), Amount					$ 20,000								20,000
Common Shares issued for debt (D), Shares					100,000,000
Common Shares issued for debt (D), Amount					$ 10,000								10,000
Common Shares issued for debt (E), Shares					150,000,000
Common Shares issued for debt (E), Amount					$ 15,000								15,000
Sale of owned and issued shares of Regen Biopharma, Inc.							50,000						50,000
Shares of subsidiary issed to consultant							22,440						22,440
Loss recognized on issuance of shares for less than fair value							587,500						587,500
Accumulated Other Comprehensive Income (Loss)												(2,000)	(2,000)
Noncontrolling interest recognized							55,786			(55,786)			0
Net Income (loss)								(856,892)					(856,892)
Ending balance, Shares at Dec. 31, 2014	94,852	725,409	40,000	2,063,821	3,729,900,942	0
Ending balance, Amount at Dec. 31, 2014	$ 9	$ 73	$ 4	$ 207	$ 372,989	$ 0	17,278,665	21,604,464		(35,786)	509,355	(41,335,361)	(1,605,363)
Common Shares issued for debt, Shares					103,030,303
Common Shares issued for debt, Amount					$ 10,303		6,697						17,000
Common Shares issued for debt (B), Shares					200,000,000
Common Shares issued for debt (B), Amount					$ 20,000								20,000
Common stock of subsidiary issued for services, Amount							140,000						140,000
Common stock of subsidiary issued for services (B), Amount							63,739						63,739
Common stock of subsidiary issued for Debt, Amount							558,575						558,575
Common stock of subsidiary issued for Debt (B), Amount							175,000						175,000
Common stock of subsidiary issued for Debt (C), Amount							50,000						50,000
Common stock of subsidiary issued for Debt (D), Amount							100,000						100,000
Preferred Shares of subsidiary issued for Purchase of Patent							100						100
Preferred Shares of subsidiary issued pursuant to contractual obligations							3,154						3,154
Preferred Shares of subsidiary issued to Consultants for Services							420						420
Sale of owned and issued shares of Regen Biopharma, Inc.							20,000						20,000
Recognition of beneficial conversion feature, convertible note							300,000						300,000
Loss recognized on issuance of shares for less than fair value							8,393,947						8,393,947
Accumulated Other Comprehensive Income (Loss)												1,000	1,000
Noncontrolling interest recognized							(467,943)			467,943			0
Regen Restricted Stock Award compensation expense recognized							132,602						132,602
Net Income (loss)								(9,344,958)					(9,344,958)
Ending balance, Shares at Mar. 31, 2015	94,852	725,409	40,000	2,063,821	4,032,931,245	0
Ending balance, Amount at Mar. 31, 2015	$ 9	$ 73	$ 4	$ 207	$ 403,292	$ 0	26,754,956	12,259,506		432,174	509,355	(41,334,361)	(974,784)
Common Shares issued for debt, Shares					200,000,000
Common Shares issued for debt, Amount					$ 20,000								20,000
Common stock of subsidiary issued for Debt, Amount							40,000						40,000
Common stock of subsidiary issued for Debt (B), Amount							15,000						15,000
Common stock of subsidiary issued for Debt (C), Amount							15,000						15,000
Common stock of subsidiary issued for Debt (D), Amount							50,000						50,000
Preferred Shares of subsidiary issued pursuant to contractual obligations							143						143
Preferred Shares of subsidiary issued to Consultants for Services							20						20
Loss recognized on issuance of shares for less than fair value							1,077,425						1,077,425
Noncontrolling interest recognized							216,981			(216,981)			0
Net Income (loss)								(1,829,173)					(1,829,173)
Ending balance, Shares at Jun. 30, 2015		725,409	40,000	2,063,821	4,232,931,245	0
Ending balance, Amount at Jun. 30, 2015		$ 73	$ 4	$ 207	$ 423,292	$ 0	28,417,291	10,430,333	$ 215,193	215,193	509,355	(41,333,361)	(1,337,603)
Common stock of subsidiary issued for Cash, Amount							33,333						33,333
Common stock of subsidiary issued for Cash (B), Amount							16,667						16,667
Common stock of subsidiary issued for services, Amount							61,836						61,836
Common stock of subsidiary issued for services (B), Amount							19,941						19,941
Loss recognized on issuance of shares for less than fair value							75,000						75,000
Accumulated Other Comprehensive Income (Loss)												(35,280)	(35,280)
Noncontrolling interest recognized							133,143			(133,143)			0
Regen Restricted Stock Award compensation expense recognized							$ 247,588						247,588
Net Income (loss)								(725,935)					(725,935)
Ending balance, Shares at Sep. 30, 2015		725,409	40,000	2,063,821	4,232,931,245	0	29,004,809
Ending balance, Amount at Sep. 30, 2015		$ 73	$ 4	$ 207	$ 423,292	$ 0	$ 29,004,809	$ 9,704,398		$ 82,050	$ 509,355	$ (41,368,641)	$ (1,644,443)